EdgeTestMarket TodayOptions TodayIPO
Start free

VALIANTLABValiant Laboratories Limited

Rs 125.87▼ -1.99%
Market closedEquity EOD 26 Oct
Compare
52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.83.1% up the range
Rs 50Rs 141
VALIANTLAB price
Daily candles, adjusted for splits and bonus issues so a corporate action does not show as a crash. Pick a window from one month to the full history, add indicators, or open it full screen.
EOD 26 Oct
IndicatorsVolume

Loading VALIANTLAB price...

At a glance
Each figure is shown against the company's sector (the track: the dot is this company, the tick is the sector middle) and, where we hold the yearly filings, against its own recent years (the small trend line).
Market capWhat the whole company is worth on the stock market today: share price times the number of shares. It measures size, not quality.
Rs 684 cr
Larger than 21% of 110 peers
sector middle Rs 4,734 cr
P/EPrice to earnings: how many rupees investors pay for each rupee of profit the company made over the last twelve months. Compare it with similar companies rather than reading it alone.
44.3x
Higher than 67% of 93 peers
sector middle 35.5x
Price to bookPrice to book: the share price divided by the shareholders' money per share in the latest balance sheet. Around 1 means the market values the company close to its book value.
2.2x
Lower than 71% of 107 peers
sector middle 3.9x
ROEReturn on equity: the year's profit as a percentage of the shareholders' money in the business. It shows how much the company earns on what its owners have put in.
5.2%
Lower than 75% of 101 peers
sector middle 11.8%
FY25 -0.9%FY26 -1.1%
ROCEReturn on capital employed: operating profit as a percentage of all the long-term money in the business, owners' and lenders'. It shows how well the company uses its capital, whatever the mix of debt.
0.8%
Lower than 88% of 105 peers
sector middle 14.9%
FY24 -0.2%FY26 0.8%
Debt to equityBorrowings divided by shareholders' money. 0 means no borrowings; 1 means it owes as much as its owners have put in. Not shown for banks and lenders, whose borrowing is their business.
0.14
Lower than 56% of 107 peers
sector middle 0.19
FY24 0.32FY26 0.14
Dividend yieldDividends paid over the last year as a percentage of the company's market value: roughly what Rs 100 of shares paid out in cash.
0.0%
Lower than 62% of 109 peers
sector middle 0.1%
Sales growthHow much the latest quarter's sales grew against the same quarter a year earlier.
+146.2%
Higher than 98% of 102 peers
sector middle +17.7%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

What the numbers say
Short lines written by fixed rules from the company's own filings and shareholding. A line appears only when the figures cross the rule (for example sales growing three years running), and each names the numbers behind it. Nothing here is a view on whether to own the share.

Latest quarterIn the quarter to June 2026 (results filed 10 Aug 2026), sales rose 146.2% from a year earlier to Rs 115 cr and profit rose 1058.9% to Rs 21.1 cr.

Worth watching
  • Reported a loss in FY25 and FY26.
  • Profit before interest covered interest 1.4 times in FY26 (Rs 2 cr of interest).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

How the share moved on results
For each quarterly result we hold: the change from the share's close on the last trading day before the filing to its close on the first trading day after it. Results can land during market hours or after the close, and this window covers both. It shows what happened, not what will happen next time.

Over the last 12 results, the share rose on 3 and fell on 9, and moved by 3% or more on 6.

Q4 FY24Q3 FY25Q2 FY26Q1 FY27

Q1 FY27: results filed 10 Aug 2026. The share went from its close on 7 Aug 2026 to its close on 11 Aug 2026 +10.23%.

Where every Rs 100 of sales goes
From the company's own yearly results. Each year is scaled to that year's sales, so you compare shares, not size: how much went on running costs, depreciation, interest and tax, and how much was left as profit.
2 financial years
Sales, last 12 months
Rs 306 Cr
Profit, last 12 months
Rs 16 Cr
Earnings per share
Rs 2.8
Profit growth (qtr, YoY)
+1058.93%

Of every Rs 100 of sales in FY26, Rs 97 went on running costs, Rs 2.5 on depreciation, Rs 0.8 on interest and Rs 1.7 on tax; the year ended in a loss.

FY25
103
FY26
97
Sales (Rs 100)Other incomeLoss for the yearRunning costsDepreciationInterestTax

Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.

How fast it has grown
Compound growth per year in sales, profit and earnings per share between financial years, from the company's own results. A span appears only if our filings cover both ends of it.
Sales
Latest qtr
+146.2%
Profit
Latest qtr
+1058.9%

Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.

Health check, year by year
Margins, returns, debt and interest cover for each financial year. Each row is coloured against this company's own usual level, so you see what is improving and what is slipping.
MeasureFY24FY25FY26
Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales.--3.4%2.7%
Net marginProfit after everything, per Rs 100 of sales.--1.6%-1.4%
ROEProfit as a percentage of shareholders' money (from the March balance sheet).--0.9%-1.1%
ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'.-0.2%-0.4%0.8%
Debt to equityBorrowings divided by shareholders' money. Lower is safer.0.32x0.52x0.14x
Interest coverHow many times operating profit covers the interest bill. Higher is safer.--6.5x1.4x

Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).

What it owns, and how that is paid for
Straight from the March balance sheet in the company's annual filing. Both bars are the whole balance sheet: what the company owns, and where the money for it came from.
as at 2026-03-31

At FY26 it owned Rs 464 Cr of assets. Its owners funded 67% of that and borrowings 10%.

What it owns
50%
10%
20%
13%
Plant, property and projects233 Cr
Goodwill and intangibles0 Cr
Investments26 Cr
Inventory45 Cr
Owed by customers94 Cr
Cash and bank7 Cr
Everything else59 Cr
How that is paid for
67%
10%
20%
Shareholders311 Cr
Borrowings45 Cr
Owed to suppliers94 Cr
Other liabilities14 Cr
Cash and equivalents
Rs 4 Cr
Net debt
Rs 15 Cr
Current ratio
1.91x
short-term assets per rupee due soon
Book value / share
Rs 57
Return on assets
3.5%
EV / EBITDA
80.2x

From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.

Where the cash went
Profit is an accounting figure; cash flow is what actually moved. Cash from running the business, plus or minus what was spent on or received from investments, plus or minus what came from or went to lenders and shareholders, equals the change in cash.

In FY26 the business itself brought in Rs -10 Cr, spent Rs 34 Cr on plant and equipment, and cash fell by Rs 1 Cr over the year.

From running the business
-10 Cr
Spent on or received from investing
+7 Cr
From or to lenders and shareholders
+2 Cr
Net change in cash
-1 Cr

Full financial year to 2026-03-31, from the company's cash flow statement.

Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Pharmaceuticals · 142
P/E44.32vs 35.49 median
Cheapest: AHCL 4.23Priciest: ORCHPHARMA 665.33
Net margin5.23%vs 11.41% median
Lowest: ZOTA -17.13%Highest: NATCOPHARM 32.85%
Revenue growth146.22%vs 17.74% median
Lowest: NECLIFE -99.99%Highest: SPARC 314.11%
Compared against
AAREYDRUGSAARTIDRUGSAARTIPHARMABBOTINDIAACCPLACUTAASAHCLAJANTPHARMAKUMSALBERTDAVDALIVUSALKEMALPAAMANTAAMBALALSAAMRUTANJANANUHPHRAPLLTDASTRAZENAUROPHARMABAJAJHCAREBALAXIBALPHARMABETABIOCONBIOFILCHEMBLISSGVSBLUEJETBMLLBPLPHARMABROOKSCAPLIPOINTCIPLACOHANCECONCORDBIOCORONACURISDCALDIVISLABDRREDDY

Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.

Peers side by side
Every company in the same NSE industry group that we hold figures for, largest first. Tap any heading to sort by it. The same figures as the At a glance tiles, worked out the same way for every company.
Pharmaceuticals · 40 shown
Company
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.17 L cr34.5x5.0x14.4%17.9%0.0520.2%+10.5%0.94%
DIVISLAB
Divi's Laboratories Limited
2.40 L cr82.1x14.3x17.4%19.0%0.0026.1%+27.8%0.33%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.73 L cr76.9x9.4x11.4%-0.7612.1%+50.8%0.74%
ZYDUSLIFE
Zydus Lifesciences Limited
1.16 L cr25.9x4.3x15.5%19.2%0.4016.1%+22.0%0.96%
LAURUSLABS
Laurus Labs Limited
1.11 L cr101.8x21.0x20.1%19.7%0.4415.0%+29.1%0.08%
CIPLA
Cipla Limited
1.09 L cr32.5x3.2x9.7%14.9%0.0111.8%+2.3%1.18%
DRREDDY
Dr. Reddy's Laboratories Limited
1.09 L cr39.0x2.8x7.0%-0.158.3%-1.5%0.61%
MANKIND
Mankind Pharma Limited
95,486 cr46.8x5.9x12.5%13.7%0.3814.0%+12.9%0.04%
AUROPHARMA
Aurobindo Pharma Limited
91,489 cr24.8x2.4x9.8%13.6%0.2010.6%+16.3%0.25%
LUPIN
Lupin Limited
89,616 cr16.2x4.0x24.7%28.4%0.2618.5%+32.0%0.61%
GLENMARK
Glenmark Pharmaceuticals Limited
62,812 cr35.0x6.0x17.1%16.2%0.0010.1%+23.1%0.22%
ALKEM
Alkem Laboratories Limited
60,134 cr27.9x4.3x15.4%18.8%0.1114.6%+10.9%1.02%
BIOCON
Biocon Limited
53,581 cr97.3x1.6x1.1%2.9%0.402.4%+10.0%0.17%
IPCALAB
IPCA Laboratories Limited
49,182 cr37.5x6.1x14.4%16.4%0.0713.6%+20.8%0.11%
GLAND
Gland Pharma Limited
46,913 cr41.5x4.5x10.9%13.7%0.0216.8%+19.6%0.63%
AJANTPHARM
Ajanta Pharma Limited
42,381 cr37.2x9.4x25.1%29.4%0.0519.6%+24.8%0.83%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
41,436 cr38.8x18.3x46.8%55.4%0.0027.0%+16.6%1.72%
EMCURE
Emcure Pharmaceuticals Limited
33,767 cr33.4x6.8x20.5%25.1%0.2410.5%+22.9%0.17%
SAILIFE
Sai Life Sciences Limited
30,682 cr85.4x12.3x14.6%18.1%0.0416.1%+11.7%0.00%
WOCKPHARMA
Wockhardt Limited
29,316 cr71.8x5.9x7.8%6.5%0.4011.6%+25.9%0.00%
PPLPHARMA
Piramal Pharma Limited
25,906 cr-3.2x-3.8%0.8%0.67-3.4%+17.4%0.07%
RUBICON
Rubicon Research Limited
24,647 cr84.9x19.1x22.4%24.3%0.2014.9%-0.00%
NEULANDLAB
Neuland Laboratories Limited
24,582 cr49.1x13.1x26.6%23.1%0.1021.0%+119.2%0.06%
GRANULES
Granules India Limited
20,333 cr30.5x4.0x13.0%16.0%0.2611.8%+22.0%0.18%
COHANCE
Cohance Lifesciences Limited
17,735 cr115.6x4.5x2.6%4.8%0.043.9%-23.1%0.00%
SHILPAMED
Shilpa Medicare Limited
17,620 cr59.0x6.8x11.5%12.4%0.2517.7%+44.9%0.06%
CAPLIPOINT
Caplin Point Laboratories Limited
17,282 cr26.1x4.8x18.7%22.0%0.0029.6%+19.6%0.26%
PFIZER
Pfizer Limited
16,869 cr30.9x4.0x17.5%22.9%0.0028.6%+8.3%4.46%
ONESOURCE
Onesource Specialty Pharma Limited
16,019 cr-2.8x-0.8%0.5%0.22-3.1%+37.2%0.00%
ALIVUS
Alivus Life Sciences Limited
15,490 cr25.7x4.7x18.1%21.8%0.0023.3%+6.4%0.40%
ERIS
Eris Lifesciences Limited
15,318 cr23.5x3.9x17.1%15.7%0.5920.6%+13.0%0.00%
ASTRAZEN
AstraZeneca Pharma India Limited
15,129 cr174.2x17.3x19.4%25.5%0.007.0%+29.7%0.53%
APLLTD
Alembic Pharmaceuticals Limited
15,064 cr21.7x2.6x12.2%12.8%0.248.9%+25.7%1.44%
JUBLPHARMA
Jubilant Pharmova Limited
14,805 cr42.3x2.1x5.0%6.4%0.454.1%+17.3%0.54%
NATCOPHARM
Natco Pharma Limited
14,145 cr12.4x1.5x12.4%16.3%0.0832.9%-44.7%0.64%
CONCORDBIO
Concord Biotech Limited
13,717 cr50.3x6.8x13.5%16.6%0.0024.6%+26.2%0.82%
ACUTAAS
Acutaas Chemicals Limited
13,708 cr71.3x8.3x22.6%27.7%0.0226.5%+59.1%0.09%
MARKSANS
Marksans Pharma Limited
13,443 cr26.0x4.5x17.1%17.5%0.0116.4%+35.6%0.27%
CORONA
CORONA Remedies Limited
12,485 cr62.7x16.7x26.6%29.3%0.1913.5%-0.00%
VALIANTLAB
Valiant Laboratories Limited
684 cr44.3x2.2x5.2%0.8%0.145.2%+146.2%0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
2 years · 12 quarters
Full financial years - the long arc of the business.
Sales growth
-
a year, 3 years
Profit growth
-
a year, 3 years
Operating margin
2.7%
latest year
Sales by financial yearRs 238 Cr
Net profit by financial yearRs -3 Cr
FY252 full years · hover a yearFY26

Operating margin has gone from -3.4% to 2.7% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.

Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 26 Oct
RSI (14) - momentum
53.2Neutral
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
49%Below average - weaker conviction
today 49%20d avg 80.2%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50-DMA
+10.06%
vs 200-DMA
+62.56%
1-month
+3.82%
3-month
+104.67%
1-year
+50.69%
Realized vol (30d)
51.3%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months

Insider trading data unavailable.

Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months

Announcements unavailable.

Want to test a strategy on VALIANTLAB?

Backtest an equity strategy on real market data, free - no card needed.

Start free

Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.